Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer
diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora …

At present, prostate cancer remains the second most occurring cancer in men, in Europe.
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …

The present article highlights the important progress made in the last two decades in the
fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based …

This paper is the first of a Series on theranostics that summarises the current landscape of
the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we …

Radiotherapy, where ionizing radiation is locally delivered either through an external beam
or by surgically implanting radionuclide-based seeds in the tumor, is one of the gold …